Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
06 11 2023
06 11 2023
Historique:
received:
30
03
2023
accepted:
24
07
2023
medline:
10
11
2023
pubmed:
23
9
2023
entrez:
23
9
2023
Statut:
ppublish
Résumé
WGS has the potential to detect resistance-associated mutations and guide treatment of MDR TB. However, the knowledge base to confidently interpret mutations associated with the new and repurposed drugs is sparse, and phenotypic drug susceptibility testing is required to detect resistance. We screened 900 Mycobacterium tuberculosis complex genomes from Ireland, a low TB incidence country, for mutations in 13 candidate genes and assessed their association with phenotypic resistance to bedaquiline, clofazimine, linezolid, delamanid and pretomanid. We identified a large diversity of mutations in the candidate genes of 195 clinical isolates, with very few isolates associated with phenotypic resistance to bedaquiline (n = 4), delamanid (n = 4) and pretomanid (n = 2). We identified bedaquiline resistance among two drug-susceptible TB isolates that harboured mutations in Rv0678. Bedaquiline resistance was also identified in two MDR-TB isolates harbouring Met146Thr in Rv0678, which dated back to 2007, prior to the introduction of bedaquiline. High-level delamanid resistance was observed in two isolates with deletions in ddn, which were also resistant to pretomanid. Delamanid resistance was detected in two further isolates that harboured mutations in fbiA, but did not show cross-resistance to pretomanid. All isolates were susceptible to linezolid and clofazimine, and no mutations found were associated with resistance. More studies that correlate genotypic and phenotypic drug susceptibility data are needed to increase the knowledge base of mutations associated with resistance, in particular for pretomanid. Overall, this study contributes to the development of future mutation catalogues for M. tuberculosis complex isolates.
Sections du résumé
BACKGROUND
WGS has the potential to detect resistance-associated mutations and guide treatment of MDR TB. However, the knowledge base to confidently interpret mutations associated with the new and repurposed drugs is sparse, and phenotypic drug susceptibility testing is required to detect resistance.
METHODS
We screened 900 Mycobacterium tuberculosis complex genomes from Ireland, a low TB incidence country, for mutations in 13 candidate genes and assessed their association with phenotypic resistance to bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
RESULTS
We identified a large diversity of mutations in the candidate genes of 195 clinical isolates, with very few isolates associated with phenotypic resistance to bedaquiline (n = 4), delamanid (n = 4) and pretomanid (n = 2). We identified bedaquiline resistance among two drug-susceptible TB isolates that harboured mutations in Rv0678. Bedaquiline resistance was also identified in two MDR-TB isolates harbouring Met146Thr in Rv0678, which dated back to 2007, prior to the introduction of bedaquiline. High-level delamanid resistance was observed in two isolates with deletions in ddn, which were also resistant to pretomanid. Delamanid resistance was detected in two further isolates that harboured mutations in fbiA, but did not show cross-resistance to pretomanid. All isolates were susceptible to linezolid and clofazimine, and no mutations found were associated with resistance.
CONCLUSIONS
More studies that correlate genotypic and phenotypic drug susceptibility data are needed to increase the knowledge base of mutations associated with resistance, in particular for pretomanid. Overall, this study contributes to the development of future mutation catalogues for M. tuberculosis complex isolates.
Identifiants
pubmed: 37740935
pii: 7281310
doi: 10.1093/jac/dkad252
pmc: PMC10683940
doi:
Substances chimiques
OPC-67683
0
Antitubercular Agents
0
pretomanid
0
Clofazimine
D959AE5USF
Linezolid
ISQ9I6J12J
Diarylquinolines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2637-2644Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0261720
pubmed: 33972244
Lancet Infect Dis. 2013 Feb;13(2):137-46
pubmed: 23158499
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32907992
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1564-1568
pubmed: 32053752
Antimicrob Agents Chemother. 2014 May;58(5):2979-81
pubmed: 24590481
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29167290
Lancet Microbe. 2022 Apr;3(4):e265-e273
pubmed: 35373160
J Antimicrob Chemother. 2019 Sep 1;74(9):2605-2616
pubmed: 31119271
Tuberculosis (Edinb). 2009 Jan;89(1):84-90
pubmed: 18851927
Tuberculosis (Edinb). 2018 Jan;108:186-194
pubmed: 29523322
PeerJ. 2018 Nov 13;6:e5895
pubmed: 30479891
J Antimicrob Chemother. 2022 May 29;77(6):1685-1693
pubmed: 35260883
N Engl J Med. 2022 Jan 6;386(1):93-94
pubmed: 34986292
Antimicrob Agents Chemother. 2012 May;56(5):2743-5
pubmed: 22371899
BMC Infect Dis. 2021 Apr 8;21(1):330
pubmed: 33832459
J Antimicrob Chemother. 2015 Sep;70(9):2507-10
pubmed: 26045528
Antimicrob Agents Chemother. 2007 Apr;51(4):1534-6
pubmed: 17242139
Genome Med. 2020 Mar 6;12(1):27
pubmed: 32143680
Nat Commun. 2014 Sep 01;5:4812
pubmed: 25176035
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
Sci Rep. 2021 Sep 30;11(1):19431
pubmed: 34593898
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2542-4
pubmed: 26810645
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690
pubmed: 28031270
Indian J Med Res. 2021 Jan;154(1):85-89
pubmed: 34782533
Int J Antimicrob Agents. 2020 Apr;55(4):105912
pubmed: 31991222
Genome Med. 2020 Nov 25;12(1):104
pubmed: 33239092
Int J Tuberc Lung Dis. 2022 Jun 1;26(6):571-573
pubmed: 35650698
Emerg Infect Dis. 2021 Mar;27(3):985-987
pubmed: 33622487
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34503982
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0116421
pubmed: 34460306
Lancet Microbe. 2021 Nov;2(11):e604-e616
pubmed: 34796339
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32868333
J Antimicrob Chemother. 2022 Mar 31;77(4):880-902
pubmed: 35089314
Antimicrob Agents Chemother. 2012 May;56(5):2326-34
pubmed: 22354303
Acta Microbiol Immunol Hung. 2021 Jun 24;:
pubmed: 34174037
Lancet Microbe. 2020 Aug;1(4):e165-e174
pubmed: 32803174
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9
pubmed: 27185800
Clin Microbiol Infect. 2023 Jan;29(1):77-84
pubmed: 35961488
Am J Respir Crit Care Med. 2016 Feb 1;193(3):337-40
pubmed: 26829425